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Neuropsychologyh i g h l i g h t s
 Epileptiform discharges are presented in half of Alzheimer patients without epileptic seizures.
 Alzheimer patients with epileptiform discharges have significantly lower memory performance.
 Epileptiform discharges associate with 1.5-times faster cognitive decline in a prospective follow-up.
a b s t r a c t
Objective: While many studies suggest that patients with Alzheimer’s disease have a higher chance for
developing epileptic seizures, only a few studies are available examining independent epileptic dis-
charges. The major aims of our study was to determine the prevalence of subclinical epileptiform activity
(SEA) in AD compared to healthy elderly controls with the hypothesis that SEA is more frequent in AD
than in cognitively normal individuals. Another aim was to analyze the effect of baseline SEA captured
with electroencephalography on the progression of the disease with longitudinal cognitive testing.
Methods: We investigated 52 Alzheimer patients with no history of epileptic seizures and 20 healthy
individuals. All participants underwent a 24-hour electroencephalography, neurology, neuroimaging
and neuropsychology examination. Two independent raters analyzed visually the electroencephalograms
and both raters were blind to the diagnoses. Thirty-eight Alzheimer patients were enrolled in a 3-year
long prospective follow-up study with yearly repeated cognitive evaluation.
Results: Subclinical epileptiform discharges were recorded significantly (p:0.018) more frequently in
Alzheimer patients (54%) than in healthy elderly (25%). Epileptiform discharges were associated with
lower performance scores in memory. Alzheimer patients with spikes showed 1.5-times faster decline
in global cognitive scores than patients without (p < 0.001). The decline in cognitive performance scores
showed a significant positive correlation with spike frequency (r:+0.664; p < 0.001).
Conclusions: Subclinical epileptiform activity occurs in half of Alzheimer patients who have never suf-
fered epileptic seizures. Alzheimer patients with subclinical epileptiform activity showed accelerated
cognitive decline with a strong relation to the frequency and spatial distribution (left temporal) of spikes.
Significance: Our findings suggest the prominent role of epileptiform discharges in the pathomechanism
of Alzheimer’s disease which might serve as potential therapeutic target.
 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Alzheimer’s disease (AD) is the major cause of cognitive decline
creating ponderous economic burden on the aging societies. It is
well known that some factors modify the progression, e.g. the
onset of cognitive decline, an advanced disease stage at the time
of diagnosis, educational background, female gender, and comor-
bid cardiovascular disease (Ito et al., 2011; Devanand et al.,
2013; Doody et al., 2010).
A recently recognized concomitant condition is epilepsy. In ani-
mal models of AD, epileptic seizures are common (Palop et al.,
2008; Palop and Mucke, 2010). Also, neuropathology studies have
identified many similarities between AD and temporal lobe epi-
lepsy such as the presence of amyloid plaques, tau neurofibrils,
hippocampal sclerosis and hippocampal hyperexcitability
(Puvenna et al., 2006; Riascos et al., 2014; Tai et al., 2016). Growing
body of evidence suggests that AD patients have an increased risk
to develop epileptic seizures and seizures associate with worse
cognitive functioning (Horváth et al., 2016; Palop and Mucke,
2009). In addition to taking into account the cognitive harm of clin-
ical seizures, modern epileptology has recognized the negative
impact of epileptiform discharges on the cognitive performance
of epilepsy patients Ung et al., 2017).
Considering the harm of epileptic discharges on cognitive func-
tions in epilepsy, it is intriguing to investigate the effect of epilep-
tiform activity in AD patients without clinical seizures (subclinical
epileptiform activity- SEA) (Fisher et al., 2014). SEA could be
observed among healthy individuals (Santoshkumar et al., 2009);
however, the physiological background of the phenomenon (as a
potential marker of cortical hyperexcitability or an indicator of
an undiagnosed neurological disorder) is unclarified (McLachlan
and Luba, 2002). Many early studies demonstrated that SEA might
serve as a predictive marker for the further development of epilep-
tic seizures (Saito et al., 1987), however, it was not clarified with
sensitive neurophysiological techniques or meta-analysis (So
2010). Recent studies demonstrated that SEA might predict poor
outcome in acute vascular events (Tabaeizadeh et al., 2020), asso-
ciate with more severe symptoms in autism spectrum disorders
(Mulligan and Trauner, 2014) and predict epileptic seizures in chil-
dren with attention-deficit hyperactivity disorders (Richer et al.,
2002). There is clearly a scientific trend suggesting that SEA might
have a role in the development of many disorders affecting cogni-
tive functions (Horvath et al., 2020). It is confirmed by a recent
human study that SEA might impair the cognitive functions of
AD patients (Vossel et al., 2016); however, these results have not
been replicated yet.
The aim of our prospective study was to determine the preva-
lence of SEA in AD compared to healthy elderly controls with the
hypotheses that 1, SEA is more frequent in AD than in cognitively
normal individuals, and 2, baseline SEA captured with electroen-
cephalography (EEG) associate with faster progression of the dis-
ease. We also aimed to establish the link between the temporal
and spatial distribution of epileptiform spiking and cognitive
decline.Fig. 1. FLOW-CHART OF PARTICIPANT RECRUITMENT AND ENROLLMENT. AD:
Alzheimer’s disease; HC: healthy control; EEG: electroencephalography; SEA:
subclinical epileptiform activity.2. Materials and methods
2.1. Participants
We studied 80 AD patients with clinically typical, predomi-
nantly memory-associated symptoms who met the diagnostic cri-
teria of the National Institute of Aging- Alzheimer’s Association
(NIA-AA) for probable AD (McKhann et al., 2011) and 20 cogni-
tively healthy controls (HC) in the Department of Neurology of
National Institute of Clinical Neurosciences in Budapest and in1983the Department of Neurology of Kaposi Mór County Hospital in
Kaposvár, Hungary between 2015 and 2019. All subjects were
native Hungarians.
We collected medical history including collateral data and med-
ical records for excluding those patients with epileptic seizures or
seizure like events. Participants who had epileptic seizures or ele-
vated risk for epileptic seizures including prior infection of central
nervous system, clinically significant brain lesions (stroke, severe
periventricular white matter disease, white matter infarcts), head
trauma with loss of consciousness, demyelinating conditions,
hydrocephalus, untreated vitamin B12 deficiency or hypothy-
roidism, syphilis or HIV infection, major depression, schizophrenia,
electroconvulsive therapy, renal insufficiency, liver disease, signif-
icant systemic medical illness, alcohol or substance dependency,
psychoactive drugs affecting cognitive functions except antide-
mentia medication were excluded from the current analysis
(n:21). Furthermore, 7 patients with major depression measured
with neuropsychological tests were also excluded (Fig. 1).
Data of 52 AD patients were analyzed in the prevalence analysis
(studies at year 0). Data from 32 patients were used in a previous
publication of our group (Horvath et al., 2018). In that study, only
the demographic characteristics were analyzed to compare AD
patients with SEA to AD patients with epileptic seizures.
We followed our patients for 3 years and repeated the same
neuropsychology test battery each year. During the 3-year
follow-up, we excluded 5 AD patients from the prospective analy-
sis who in addition to AD suffered significant physical or mental ill-
ness potentially affecting cognitive functioning during the follow-
up period. Four AD patients developed seizures during the
follow-up period, therefore their data were excluded from the sta-
tistical analysis. Five more patients were lost to follow-up because
of being unreachable. Finally, we analyzed the prospective data of
the remaining 38 AD patients at the end of the 3rd year in the lon-
gitudinal analysis (Fig. 1).
2.2. Standard protocol approvals, registration, and phenotyping
The Hungarian Medical Research Council authorized our
research (reference number: 024505/2015). We obtained informed
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not required since all cases were mild so that all patients con-
sented for themselves.
2.3. Clinical testing
The participants underwent detailed physical, neurological, and
epileptological examination, as well as routine blood checks
including thyroid functions and vitamin B12 level. All subjects
had structural brain magnetic resonance imaging (MRI).
The controls had normal neurology status and neuropsychology
scores, normal brain MRI and blood results, and they had no cogni-
tive complaints.
2.4. Neuropsychological examination
The neuropsychological tests were carried out by trained neu-
rologists or neuropsychologists in Hungarian language at the
beginning of the study (year 0) and at the beginning of each
upcoming year (year 1, year 2, year 3) within 335–395 days follow-
ing the previous examination. We used the Hungarian version of
Addenbrooke Cognitive Examination (ACE) (Stacho et al., 2002)
as primary test battery because of its high sensitivity and speci-
ficity in the diagnosis of major neurocognitive disorders. ACE
scores range from 0 to 100, higher score represents better cognitive
performance. ACE measures six cognitive domains including orien-
tation (spatial and temporal- e.g. identification of home city of cur-
rent year), attention (e.g. counting), memory (anterograde,
retrograde and delayed recall- e.g. memorization of an address or
words), verbal fluency (category and letter- e.g. listing of animals),
language (e.g. execution of written or oral orders) and visuo-spatial
skills (e.g. clock drawing and copying of a cube or intersecting pen-
tagons). ACE is an accurate tool in differentiating frontotemporal
dementia and AD too, and it serves properly in the assessment of
dementia severity since Mini-Mental State Examination Score
(MMSE) can be extracted from the test data (Dudas et al., 2005).
Scores in the MMSE range from 0 to 30, higher scores denote better
cognitive performance. ACE also includes the ratio of verbal fluency
and language skills divided by the scores of delayed recall memory
and orientation (VLOM ratio). The normal value for VLOM ratio is
2.2–3.2, scores < 2.2 indicate frontotemporal type deficit while
scores > 3.2 denote Alzheimer-type impairment.
Since anxiety and depression might compromise cognitive func-
tions, we also recorded the Hungarian version of Spielberger State
and Trait Anxiety Inventory (STAI) (Sipos and Sipos, 1983) and
Beck Depression Inventory II (BDI-II) (Miklosi et al., 2011). Based
on large samples, <45 value on STAI represents low level of anxiety
in both the trait and state category (Horvath et al., 2016).
Scores < 13 indicate minimal depression, the 14–19 range repre-
sents mild, the range 20–28 moderate and a score higher than 29
signalizes severe depression. To increase our diagnostic accuracy,
patients with a STAI > 45 and a BDI II > 13 were not included in
our analysis (possible indicators of major depression).
Controls had MMSE > 26 (Janka et al., 1989) Addenbrooke Cog-
nitive Examination (ACE) score > 84 (Stacho et al., 2002), STAI < 45
(Sipos and Sipos, 1983), BDI II < 13 (Miklosi et al., 2011).
2.5. EEG examination
We performed 34-channel 24-hour long inpatient EEG record-
ing (Micromed Morpheus, 10–20 electrode placement system) in
all participants within 5 days following the neuropsychological
and clinical testing at the beginning of the study (year 0). EEGs dur-
ing the follow-up period were not repeated. Peri-orbital leads were
applied to aid sleep staging. We used the following EEG settings:
bipolar longitudinal montage, 10 microvolts/mm sensitivity,198430 mm/sec speed, 70 Hz low pass and 0.5 Hz high pass filter with
50 Hz notch filter on.
Subclinical epileptiform discharges were defined as paroxysmal
EEG graphoelements (spikes or sharp waves) with 20–200 ms
duration, with the disruption of background EEG activity, followed
by slow waves (Noachtar and Rémi, 2009). Two independent raters
analyzed visually the EEGs; a graphoelement was identified as
epileptiform if both raters marked it so. Both raters were blind to
the diagnoses. For avoiding misinterpretation of epileptic tran-
sients, we identified and excluded from the calculation the follow-
ing variants: wicket spikes, occipital sharp transients of sleep,
benign epileptiform transients in sleep, and rhythmic temporal
theta series in superficial sleep. Based on these evaluations, partic-
ipants were categorized into EEG positive (AD + SEA) and negative
(AD-SEA) subgroups.
The number of spikes was visually counted. The average num-
ber of spikes/hours was calculated as the total number of spikes
divided by the hours of recordings. The scalp distribution of SEA
was analyzed both visually and with the application of automatic
EEG software (Micromed SystemPLUS 98, Compumedics NeuroS-
can Curry 7). Recognition of spatial distribution of SEA was based
on the largest electronegativity corresponding to scalp electrodes
in the 10–20 electrode placement system as follows: frontal (Fp1,
Fp2, F3, F4), frontocentral (Fz), central (C3, Cz, C4), centroparietal
(Pz), frontotemporal (F7, F8), temporal (T3, T4, T5, T6), parietal
(P3, P4) and occipital (O1, O2) electrodes.2.6. Statistical analysis
IBM SPSS 20 software (https://www.ibm.com/support/pages/
ibm-spss-statistics-20-documentation) was applied for statistical
analysis. A recent study of Vossel et al. (Vossel et al., 2016) re-
ported difference in MMSE change /year in AD + SEA patients
(mean = 3.9, SD = 1.6) compared to AD-SEA patients (mean = 1.6,
SD = 2.4). Based on their results and our power calculations the
probability was equal or greater than 80% to find a significant (al-
pha = 0.05) difference between study groups in MMSE deteriora-
tion (in delta MMSE / year) with a sample size of 50. Drop of rate
(27%) was higher than calculated. In pairwise comparisons, t-
tests were used for continuous data with parametric distribution,
while Mann-Whitney U-test was applied for data with non-
parametric distribution. Distribution was analyzed with Shapiro-
Wilk test. For pairwise comparisons of categorial variables, chi-
square test was applied. Holm-Bonferroni method was applied
for correction of multiple comparisons. Logistic regression with
the age as a covariant was applied for comparison of SEA preva-
lence across AD patients and controls, since AD patients repre-
sented an older cohort.
Longitudinal changes in the neuropsychological data repre-
sented by ACE score and MMSE score (at the beginning, after 1-
year, after 2-year and after 3-year follow up) across AD + SEA
and AD-SEA patients were compared using repeated measure gen-
eral linear model (r-GLM). Linear model was selected because
Shapiro-Wilk test indicated normal distribution of ACE and MMSE
data (p > 0.05). Between subject factor was the presence (AD + SEA)
or absence of epileptiform activity (AD-SEA), while the measured
ACE and MMSE scores at 0 time point, at 1-year, at 2-year and at
3-year represented the within subject variable (dependent factor).
Greenhouse-Geisser correction was applied to report p- and F-
values for pairwise comparisons since Mauchly’s test reported that
sphericity could not be assumed (p < 0.05). Tukey-test was applied
for post-hoc analysis with Bonferroni correction to analyze
changes between different time points. We report adjusted p-
values for the multiple comparisons of 4 time points (0-, 1-, 2-,
3-year) and indicate significance where p < 0.0125.
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cognitive decline, gender, education level (represented in years of
education) and disease severity (represented in 0 timepoint MMSE
score) were added as covariates to the model. Effect of these factors
derived from the linear model was reported. P < 0.05 represented
statistically significant effect. Spearman-correlation was applied
to measure the association between progression of cognitive
decline and spike frequency.
All statistical analyses concerning EEG data were performed
using the data derived from the long-term EEG recording per-
formed at year 0.
2.7. Data availability
The data that support the findings of this study and not pre-
sented in this article are available on request from the correspond-
ing author.
3. Results
3.1. Demographics and clinical characteristics at year 0
The AD group (n: 52) was older than the control group (n: 20)
(p < 0.001). Patients were in the mild or moderate phase of the dis-
ease. Neuropsychology indicated typical AD representation of cog-
nitive impairment (deficit dominantly in orientation and episodic
memory) in all patients (Table 1). MRIs were analyzed with visual
inspection and in all patients showed characteristic bifrontal-
bitemporal atrophy as well as hippocampal atrophy typical of AD.
3.2. Prevalence, spatial distribution and spike frequency of SEA in AD
at year 0
We detected SEA in 54% of AD patients (28/52) and in 25% of
HCs (5/20), the difference is significant (p:0.018). SEA was detected
predominantly over the temporal electrodes (23/28 patients = 82%)
(Fig. 2). Temporal SEA lateralized predominantly to the left side
(12/23 = 52%), while bitemporal (6/23 = 26%) and right temporal
occurrence (5/23 = 22%) were less common (Fig. 2). In patients
with SEA, spike frequency was 0.29–6.68 spikes/hour (in average
2.02 spikes/hour). The vast majority of spikes (92%) occurred dur-Table 1




Number 20 52 -
Female sex (n; %) 9 (45%) 31
(59,6%)
0.346
Age (years, mean ± SD) 67.8 ± 4.8 75.5 ± 8 *0.01
Right handedness (%) 18 (90%) 48
(92.3%)
0.772
























Statistical tests were Chi-square for sex and handedness, t-test for age and Mann-
Whitney U-test for MMSE score, ACE score and VLOM ratio.
AD: Alzheimer’s disease, MMSE: Mini-Mental Score Examination, ACE: Adden-
brooke Cognitive Examination, VLOM ratio: sum of verbal fluency and language
scores divided by sum of orientation and delayed memory recall scores, SD: stan-
dard deviation. *indicates significant differences (p < 0.05).
1985ing sleep. Spikes appeared most frequently during stage 2 (31%)
and stage 3 (34%) sleep, while 23% of spikes were detected in stage
1 sleep. Only 4% of spikes occurred during rapid eye movement
(REM) sleep (Fig. 2).3.3. Characteristics of AD patients with and without subclinical
epileptiform activity at year 0
Based on the presence or absence of SEA in the EEG recordings
we divided our patients into two subgroups: AD + SEA (n: 28) and
AD-SEA (n: 24) respectively. Presence of SEA was not associated
with significantly different clinical or epidemiologic features of
AD patients. They did not show differences in therapeutic regime,
handedness, or in the course of dementia nor in global neuropsy-
chology scores. Furthermore, patients with SEA showed higher
(non-significant) VLOM ratios (Table 2). Analysis of various ACE
subscores related to different cognitive domains revealed that
patients with SEA had reduced performance in memory
(Md:3.84; p:0.007) and visuo-spatial scores (Md:1.05; p:0.03)
(Fig. 3). Difference in memory remained significant after Holm-
Bonferroni correction (p < 0.008).3.4. Prospective analysis of the effect of subclinical epileptiform
activity on the progression of Alzheimer’s disease at year 3
In our prospective study, we analyzed the data of 38 AD
patients who completed the 3-year long follow-up (Table 3).
AD + SEA patients (n = 21) differed only in the VLOM ratios from
AD-SEA patients (n = 17) (Md:-0.57; p:0.039). Spatial distribution
of SEA at year 0 in the AD + SEA group was the following: left tem-
poral (7/21 = 33%), right temporal (5/21 = 24%), bitemporal
(4/21 = 19%), right frontal (1/21 = 5%), bifrontal (3/21 = 14%),
biparietal (1/21 = 5%).
In the longitudinal analysis, AD + SEA patients showed signifi-
cantly faster cognitive decline represented by average yearly
decrease of total ACE scores (12.15 points/year in AD + SEA patients
and 8.17 points/year in AD-SEA patients, F:15.891; p:<0.001)
(Fig. 4) and by average yearly decrease in MMSE scores (2.71
points/year in AD + SEA patients and 2.22 points/year in AD-SEA
patients, F:9.64; p:0.01). Cohen’s d effect size for 3-year ACE
decline was 1.53 and 0.86 for 3-year MMSE decline. Significant dif-
ferences were found with Tukey post-hoc analysis across the mea-
sured time points (1st, 2nd and 3rd years) in ACE and MMSE scores
(all p’s < 0.001). The 1.5 times greater decrease in ACE and 20%
greater decrease in MMSE in the presence of SEA remained signif-
icant in the covariance weighted analysis applying the onset of
dementia (years), sex (% of females), educational level (total years)
and 0 timepoint disease severity (MMSE score). In our cohort, only
the 0 timepoint disease severity factor (MMSE score) showed sig-
nificant progression-modifying effect (F:9.661; p:<0.001 for ACE;
F:8.212, p:0.01 for MMSE). Decline in ACE score showed a signifi-
cant positive correlation with the measured baseline spike fre-
quency (year 0) (r:+0.664; p:0.001) (Fig. 5). We demonstrated
smaller but significant correlation between spike frequency and
reduction of MMSE score (r:+0.48; p:<0.01) as well. Since we found
higher prevalence of spikes in the temporal regions with promi-
nent left sided occurrence, we also measured the potential effect
of spatial distribution of spikes on the progression of cognitive
decline with ANOVA analysis comparing left, right and bitemporal
appearances (N: 16). We found non-significant trend for differ-
ences (F:3.775; p:0.051) across the 3 groups, where left did not dif-
fer from bitemporal occurrence (p:1), while right occurrence was
associated with lower non-significant decrease in ACE than left
appearance (Md: 11.85; p:0.058) (Fig. 5).
Fig. 2. NEUROPHYSIOLOGIC FEATURES OF SUBCLINICAL EPILEPTIFORM ACTIVITY (SEA) IN AD PATIENTS AT YEAR 0. A: Spike detected in the left temporal region with phase
inversion at temporal (T3) electrode in patient 005; B: Spike detected in the right frontotemporal region with maximum electronegativity at F8 electrode in patient 008; C:
Spatial distribution of SEA showing the dominant occurrence of spikes in the temporal regions with left sided predisposition.; D: Temporal distribution of SEA demonstrating
that spikes occur almost exclusively in sleep, dominantly in deep sleep.
Table 2
Epidemiologic and clinical data of the AD + SEA and AD-SEA subgroups.
Parameter AD-SEA AD + SEA p-
value
Number of patients 24 28 -
Female sex (%) 14 (58%) 17 (61%) 0.579
Memantine therapy (%) 5 (20%) 6 (21%) 0.51
Cholinesterase inhibitor therapy (%) 24 (100%) 28 (100%) 1
Age (years, mean ± SD) 73.5 ± 7.8 71.9 ± 7.5 0.441
Right handedness (%) 21 (88%) 27 (96%) 0.321
Age at the onset of dementia (years,
mean ± SD)
70.7 ± 7.5 69 ± 7.4 0.434
Duration of dementia in years with median
(interquartile range)
3 (1–4) 3 (2–3) 0.76






















Statistical tests were Chi-square for sex, antidementia medication and handedness,
t-test for age and for the onset of disease and Mann-Whitney U-test for MMSE
score, ACE score and VLOM ratio.
AD: Alzheimer’s disease; SEA: subclinical epileptiform activity; ACE: Addenbrooke
Cognitive Examination; MMSE: Mini-Mental Score Examination; VLOM ratio: sum
of verbal fluency and language scores divided by sum of orientation and delayed
memory recall scores, SD: standard deviation.
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In the current study, we analyzed 24-hour EEGs of 52 AD
patients and 20 healthy elderly controls. We demonstrated that
AD patients show significantly higher prevalence of SEA than the
control subjects (54% vs 20% respectively). Temporal distribution
of SEA showed that 65% of the discharges occur in stage 2 or deeper
sleep, while analysis of spatial occurrence revealed strong left side
dominance. In the comparison of AD patients with and without
SEA, we showed that patients with positive EEG had significantly
lower performance in memory and visuo-spatial domains. In a 3-
year prospective analysis of AD patients with repeated neuropsy-1986chological test battery, we revealed that patients with SEA showed
significantly faster progression of cognitive decline.
There are only a few studies focusing on SEA in AD with
ambiguous prevalence data. Liedorp and his colleagues found
epileptiform discharges in only 2 % of 1674 AD patients (Liedorp
et al., 2010). However, they performed only 30-min long daytime
EEGs, therefore they could not detect most of the SEA events
which, as we show in the present study, appear mostly during slow
wave sleep. Also, Vossel et al found SEA in just 6% of 42 AD
patients, that can be explained by evaluating only daytime routine
EEGs in 91% of their patients (Vossel et al., 2013). Our remarkably
higher  54% - SEA rate may be due to the fact that we analyzed 24
hours EEGs including whole night sleep. It has been clearly shown
in several epilepsy studies that interictal epileptiform discharges
accumulate in sleep (Sammaritano et al., 1991; Steriade, 2003)
and we had similar findings in AD patients in our previous study
(Horvath et al., 2017) and in the current one as well (92% of spikes
occurred in sleep). In the study of Vossel, the routine EEG was nor-
mal in 60% of AD patients who had manifest epileptic seizures,
while sleep deprived serial EEGs showed epileptiform discharges
only in 16% (Vossel et al., 2013). In our previous study we also
showed that 1-hour sleep recording is twenty-times more sensitive
in detecting epileptiform activity than 1-hour awake EEG (Horvath
et al., 2017). Thus, the possible explanation for our finding of ele-
vated SEA rate is the higher sensitivity of long-term EEG containing
sleep recordings. This is supported by another study about the
temporal distribution of SEA in AD showing that epileptic activity
occurs almost exclusively (90%) during sleep (Vossel et al, 2016).
Congruently with our data, these authors found SEA in 42% of AD
patients.
In our healthy control sample, the relatively high incidence of
SEA (25%) is curious; however, some studies also found increased
risk for epileptiform event by non-epileptic elderly. In the study
of McBride et al, epileptiform discharges were reported in 26% of
94 patients by patients aged 60 years and older using long-term
EEG monitoring (McBride et al., 2002). Others found intermittent
rhythmic delta activity in 17% of patients at the age 90 + applying
1-hour EEG recordings (Peltz et al., 2002). A study from Chochoi
et al identified epileptiform discharges in 28% of 43 elderly patients
Fig. 3. DOMAIN SPECIFIC CHARACTERISTICS OF PATIENTSWITH (AD + SEA) ANDWITHOUT SUBCLINICAL EPILEPTIFORM ACTIVITY (AD-SEA) AT YEAR 0. Mann-Whitney U-test
was applied for pairwise comparisons. * indicates significant differences (p < 0.008, after Holm-Bonferroni correction). AD: Alzheimer’s disease; SEA: subclinical epileptiform
activity.
Table 3
Baseline epidemiologic and clinical data of the AD-SEA and AD + SEA patient groups
that completed the 3-year prospective follow-up.
Parameter AD-SEA AD + SEA p-
value
Number of patients 17 21 -
Female sex (n; %) 11 (65%) 11 (52%) 0.33
Memantine therapy (n; %) 4 (24%) 5 (24%) 0.94
Cholinesterase inhibitor therapy (n; %) 17 (100%) 21 (100%) 1
Age (years, mean ± SD) 74.2 ± 7.3 71.5 ± 5.9 0.22
Right handedness (%) 17 (100%) 21 (100%) 1
Age at the onset of dementia (years,
mean ± SD)
70.8 ± 7.2 68.6 ± 5.5 0.304
Duration of dementia in years with
median score (median; interquartile
range)
3 (3–4) 3 (3–3) 0.055





MMSE median score (interquartile range) 18 (15.5–
22.5)
20 (16–21) 0.37
ACE score (mean ± SD) 65.5 ± 9.1 65.5 ± 12.5 0.98





Statistical tests were Chi-square for sex, antidementia medication and handedness,
t-test for age, for the onset of disease, for ACE score and Mann-Whitney U-test for
MMSE score and VLOM ratio. * indicates significant differences (p < 0.05).
AD: Alzheimer’s disease; SEA: subclinical epileptiform activity; ACE: Addenbrooke
Cognitive Examination; MMSE: Mini-Mental Score Examination; VLOM ratio: sum
of verbal fluency and language scores divided by sum of orientation and delayed
memory recall scores, SD: standard deviation.
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Mayo Clinic proposes that SEA is presented in 12% of the healthy
elderly (Davidson and Davidson, 2012). The incidence of SEA
reaches 50% by non-epileptic elderly with syncope (Hughes and
Zialcita, 2000). The significance of SEA in healthy elderly needs fur-
ther studies in larger cohorts. As it has been reported by Vossel
(Vossel et al., 2013) and was confirmed by our current findings
too, SEA occurs in AD significantly more frequently than in healthy
elderly. Interestingly, at the time of diagnosis (first neuropsychol-
ogy testing) higher SEA did not associate with reduced global cog-
nitive scores, however the more sensitive subscores of cognitive
domains revealed associations to more severe impairment of1987memory and visuo-spatial skills in our cohort. These findings sug-
gest that SEA might serve as an indicator of faster progressing AD
and become a more important contributor of disease progression
in the later course of AD. These results need further investigations.
The spatial distribution of epileptiform discharges was scruti-
nized in only five studies; four of them analyzed AD patients with
epileptic seizures (interictal epileptiform discharges) (Vossel et al.,
2013; Cretin et al., 2016; Rao et al., 2009; Sarkis et al., 2016) and
one of them investigated AD patients with SEA only (Vossel
et al., 2016). In the summary of these reports, eighty percent of
the discharges appeared in the frontotemporal regions, and 60%
of them on the left side. In our study, SEA appeared almost exclu-
sively in the temporal/fronto-temporal areas, involving the left
side in 52%, the bitemporal areas in 26% and the right temporal
electrodes in 22%. In view of the known temporal and frontal
involvement of AD-related morphology changes, the frontotempo-
ral dominance of the epileptiform activity is not surprising. How-
ever, the overwhelming left dominance of epileptiform activity in
a neurodegenerative condition considered symmetric or leastwise
bilateral, is curious. Noticeably, in frontotemporal dementia, a
more severe left sided atrophy is a frequent imaging finding;
nowadays we even consider this phenomenon a diagnostic hall-
mark (Frisoni et al., 1999). Interestingly, the strong left side dom-
inance of interictal epileptiform discharges has been
demonstrated in epilepsy studies as well (Doherty et al., 2003). If
we accept that SEA or interictal activity are more frequent in the
left temporal area and that higher spike frequency associate with
faster cognitive decline, the clinical significance of this ‘‘left side
phenomenon” warrants further investigations both in epilepsy
and in neurodegenerative research.
The high prevalence of SEA is important if we consider the 1.5-
times faster progression of cognitive deterioration of AD patients
with the presence of SEA. The only available study in the literature
focusing on the impact of SEA in AD had similar results (Vossel
et al., 2016). In that study of Vossel et al, AD + SEA patients suffered
2.5-times faster decline in their yearly measured MMSE scores
than patients with no SEA (Vossel et al., 2016). This finding
remained significant even after correcting for the effects of age,
gender and educational differences, similarly to our findings. In
our cohort, we found smaller, 1.22-times faster decline in MMSE
Fig. 5. RESULTS OF LONGITUDINAL PROSPECTIVE FOLLOW-UP AT YEAR-3 IN RELATION TO BASELINE (YEAR-0) FREQUENCY AND SPATIAL DISTRIBUTION OF EPILEPTIFORM
SPIKES. A: the decline in ACE scores shows strong positive (r:+0.664) and significant (p < 0.001) correlation with spike frequency. B: left temporal (n:7) and bitemporal (n:4)
spikes associate with faster cognitive decline than right spikes (n:5) with marginal significance (p:0.051). ACE: Addenbrooke Cognitive Examination.
Fig. 4. RESULTS OF LONGITUDINAL PROSPECTIVE FOLLOW-UP. AD + SEA patients show significant (p < 0.001), 1.5-times higher decline in total ACE scores than AD-SEA
patients using repeated general linear model. * indicates significant differences (p < 0.001). AD: Alzheimer’s disease; SEA: subclinical epileptiform activity; ACE: Addenbrooke
Cognitive Examination.
Andras Attila Horvath, A. Papp, J. Zsuffa et al. Clinical Neurophysiology 132 (2021) 1982–1989scores in patients with SEA. The slower progression rate in MMSE
scores might be explained by the differences among the subjects of
the two study samples in both the AD + SEA and AD-SEA groups
(2.71 points/year in AD + SEA patients and 2.22 points/year in
AD-SEA patients in our report vs 3.9 points/year in patients with
epileptiform activity vs. 1.6 points/year in patients without in Vos-
sel’s experiment). In our cohort, we analyzed older patients (aver-
age age for prospective study was 73 in our cohort and ~ 61 in
Vossel’s study), with shorter duration of dementia (~3 years in
our study vs ~ 5 years in Vossel’s experiment) and with higher pro-
portion of patients taking antidementia medication (24% for
Memantine and 100% for cholinesterase inhibitor therapy in our
study vs 2.5% for Memantine and 56% for cholinesterase inhibitor
therapy in Vossel’s report). All of these factors might influence
the progression of AD. However, we could replicate the major strik-
ing results with a more sensitive neuropsychological test battery
(ACE versus MMSE) and larger sample size (38 vs 26 patients).
We also revealed a direct link between spike activity and cognitive
decline with the demonstration of strong correlation across spike
frequency and decline in cognitive scores.1988There are limitations to our study. Firstly, we did not perform
EEG examination at the end of the follow-up, so there is a possibil-
ity that spike frequency and spatial distribution have changed dur-
ing the follow-up period. Another important limitation is that
positron emission tomography, cerebrospinal fluid analysis or
genetic testing were not applied in the current experiment. Fur-
thermore, AD group was significantly older than the control group
(75.5 ± 8 vs 67.8 ± 4.8 years respectively), however, statistical anal-
ysis was corrected for age. The strengths of the current report are
the rigorous patient selection, the long follow-up period, and the
application and analysis of long-term EEG containing sleep.
To conclude, 24-hour EEG recording detects subclinical epilepti-
form activity in more than half of the AD patients. SEA appears typ-
ically in the frontotemporal areas, predominantly in the left
hemisphere and it seems to accelerate the progression of AD. Based
on our findings it seems reasonable that development of new
antiepileptic drugs targeting SEA control might represent a promis-
ing a novel strategy to slow cognitive decline in Alzheimer’s
disease. More studies are required to further elucidate the impor-
tance of epileptiform activity in neurodegenerative disorders.
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